Fabrication of acetylated carboxymethylcellulose coated hollow mesoporous silica hybrid nanoparticles for nucleolin targeted delivery to colon adenocarcinoma

Nejabat, Mojgan; Mohammadi, Marzieh; Abnous, Khalil; Taghdisi, Seyed Mohammad; Ramezani, Mohammad; Alibolandi, Mona

doi:10.1016/j.carbpol.2018.05.092

Cited by 60 publications

(23 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observation was in line with previous reports that FA modified in the NLC mediated the cellular uptake of the DDS through the corresponding receptor, which was beneficial for cancer therapy. 32 , 33 …”

Section: Resultsmentioning

confidence: 99%

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

The tumor microenvironment (TME) plays a significant role in weakening the effect of cancer immunotherapy, which calls for the remodeling of TME. Herein, we fabricated a nanostructured lipid carrier (NLC) to codeliver doxorubicin (Dox) and sorafenib (Sfn) as a drug delivery system (NLC/D-S). The Sfn was expected to regulate the TME of esophagus cancer. As a result, the immune response induced by Dox-related immunogenicity cell death could be fully realized. Our results demonstrated that Sfn was able to remodel the TME through downregulation of regulatory T cells (Treg), activation of effector T cells, and relieving of PD-1 expression, which achieved synergistic effect on the inhibition of primary tumor but also subsequent strong immune response on the regeneration of distant tumor.

show abstract

Section: Resultsmentioning

confidence: 99%

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Multiple prior studies have established that CT26 colon cancer cells overexpress nucleolin in cell membrane, while CHO cells basically have no nucleolin expression. [24][25][26] Cells incubated with FAM-labeled random DNA were used as the control. As shown in Figure 4, in CT26 cells, Apt-HJ generated significantly stronger fluorescent signal than free AS1411 ( Figure 4A); while in CHO cells, both Apt-HJ and free AS1411 generated weak signals ( Figure 4B).…”

Section: Affinity Of Apt-hj To Target Cancer Cellsmentioning

confidence: 99%

<p>Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin</p>

Yao¹,

An²,

Li³

et al. 2020

IJN

View full text Add to dashboard Cite

Purpose: Chemotherapy is the primary treatment for advanced colon cancer, but its efficacy is often limited by severe toxicities. Targeted therapy in the form of selectively drug delivery system (SDDS) is an important strategy to reduce adverse effects. Here, we aim to design a novel SDDS with potential for practical application using biocompatible components and scalable production process, for targeted delivery of doxorubicin (Dox) to colon cancer cells. Methods: The SDDS was made of a self-assembled DNA nano-cross (Holliday junction, or HJ) functionalized by four AS1411 aptamers (Apt-HJ) and loaded with Dox. Results: Apt-HJ had an average size of 12.45 nm and a zeta potential of −11.6 mV. Compared with the monovalent AS1411 aptamer, the quadrivalent Apt-HJ showed stronger binding to target cancer cells (CT26). A complex of Apt-HJ and doxorubicin (Apt-HJ-Dox) was formed by intercalating Dox into the DNA structure of Apt-HJ, with each complex carrying approximately 17 Dox molecules. Confocal microscopy revealed that Apt-HJ-Dox selectively delivered Dox into CT26 colon cancer cells but not the control cells. Moreover, Apt-HJ-Dox achieved targeted killing of CT26 cancer cells in vitro and reduced the damage to control cells. Importantly, compared with free Dox, Apt-HJ-Dox significantly enhanced the antitumor efficacy in vivo without boosting the adverse effects. Conclusion: These results suggest that Apt-HJ-Dox has application potential in targeted treatment of colon cancer.

show abstract

“…In the final capped particles protonation of ionisable units in the capping ensemble disrupts the electrostatic interactions with subsequent coating detachment and pore opening. This simple concept was used by Nejabat et al that reported Dox‐loaded hollow MSNs capped with the AS1411 aptamer to enhance the target delivery to colon adenocarcinoma ( Figure ) . The nanoparticles were loaded with Dox and modified with amino groups.…”

Section: Ph‐responsive Drug Delivery Systemsmentioning

confidence: 99%

New Advances in In Vivo Applications of Gated Mesoporous Silica as Drug Delivery Nanocarriers

García‐Fernández

Aznar

Martínez‐Máñez

et al. 2019

Small

112

View full text Add to dashboard Cite

One appealing concept in the field of hybrid materials is related to the design of gated materials. These materials are prepared in such a way that the release of chemical or biochemical species from voids of porous supports to a solution is triggered upon the application of external stimuli. Such gated materials are mainly composed of two subunits: i) a porous inorganic scaffold in which a cargo is stored, and ii) certain molecular or supramolecular entities, grafted onto the external surface, that can control mass transport from the interior of the pores. On the basis of this concept, a large number of examples are developed in the past ten years. A comprehensive overview of gated materials used in drug delivery applications in in vivo models from 2016 to date is thus given here.

show abstract

Fabrication of acetylated carboxymethylcellulose coated hollow mesoporous silica hybrid nanoparticles for nucleolin targeted delivery to colon adenocarcinoma

Cited by 60 publications

References 47 publications

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

<p>Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin</p>

New Advances in In Vivo Applications of Gated Mesoporous Silica as Drug Delivery Nanocarriers

Contact Info

Product

Resources

About